AWM Investment Company Inc. Acquires New Shares in Alpha Cognition Inc. $ACOG

Key Points

• AWM Investment Company Inc. has acquired a $5.79 million stake in Alpha Cognition Inc., purchasing over 1 million shares, which constitutes approximately 6.84% of the company's stock.
• Analysts have generally favorable views of Alpha Cognition, with the company receiving a "buy" rating and a consensus price target of $20.00 per share.
• Alpha Cognition reported a quarterly loss of $0.65 per share, missing estimates, and had revenues of $1.66 million, below analyst expectations.

AWM Investment Company Inc. acquired a new position in Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,095,652 shares of the company's stock, valued at approximately $5,785,000. AWM Investment Company Inc. owned approximately 6.84% of Alpha Cognition as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Salem Investment Counselors Inc. purchased a new position in Alpha Cognition during the 1st quarter valued at about $230,000. Villere ST Denis J & Co. LLC boosted its holdings in Alpha Cognition by 201.0% in the 1st quarter. Villere ST Denis J & Co. LLC now owns 71,778 shares of the company's stock worth $363,000 after buying an additional 47,928 shares during the period. Tudor Investment Corp ET AL bought a new position in Alpha Cognition in the 4th quarter worth $412,000. Alyeska Investment Group L.P. bought a new position in shares of Alpha Cognition during the 4th quarter valued at about $2,356,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Alpha Cognition in the 4th quarter valued at about $3,652,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Alpha Cognition from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Alpha Cognition in a report on Friday, May 16th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $20.00.

Insiders Place Their Bets

In other Alpha Cognition news, Director Robert James Wills bought 15,000 shares of the firm's stock in a transaction on Monday, August 18th. The shares were purchased at an average price of $8.49 per share, for a total transaction of $127,350.00. Following the completion of the transaction, the director directly owned 15,000 shares in the company, valued at approximately $127,350. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Phillip Joseph Mertz sold 27,778 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $9.00, for a total value of $250,002.00. Following the completion of the transaction, the director directly owned 22,462 shares in the company, valued at approximately $202,158. This trade represents a 55.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.00% of the stock is currently owned by company insiders.

Alpha Cognition Trading Up 7.3%

ACOG traded up $0.65 on Monday, reaching $9.55. The company had a trading volume of 46,048 shares, compared to its average volume of 87,314. Alpha Cognition Inc. has a one year low of $3.75 and a one year high of $11.54. The company has a market capitalization of $154.33 million, a P/E ratio of -5.97 and a beta of 2.71. The company has a fifty day moving average of $9.35 and a 200-day moving average of $7.65.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.19). The company had revenue of $1.66 million during the quarter, compared to analysts' expectations of $2.32 million.

Alpha Cognition Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.